PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20805522-4	2010	RESULTS: Symptomatic MAPT mutation carriers were characterized by decreased N-acetylaspartate/creatine (NAA/Cr) ratio, an index of neuronal integrity, increased myoinositol (mI)/Cr ratio, a possible marker for glial activity, decreased NAA/mI, and hippocampal atrophy (p < 0.001).	N-acetylaspartate	76-93	regulator of microtubule dynamics 1	Homo sapiens	21-25	
20805522-4	2010	RESULTS: Symptomatic MAPT mutation carriers were characterized by decreased N-acetylaspartate/creatine (NAA/Cr) ratio, an index of neuronal integrity, increased myoinositol (mI)/Cr ratio, a possible marker for glial activity, decreased NAA/mI, and hippocampal atrophy (p < 0.001).	N-acetylaspartate	104-107	regulator of microtubule dynamics 1	Homo sapiens	21-25	
20805522-4	2010	RESULTS: Symptomatic MAPT mutation carriers were characterized by decreased N-acetylaspartate/creatine (NAA/Cr) ratio, an index of neuronal integrity, increased myoinositol (mI)/Cr ratio, a possible marker for glial activity, decreased NAA/mI, and hippocampal atrophy (p < 0.001).	N-acetylaspartate	236-239	regulator of microtubule dynamics 1	Homo sapiens	21-25	
20805522-5	2010	Whereas presymptomatic MAPT mutation carriers had elevated mI/Cr and decreased NAA/mI (p < 0.001), NAA/Cr levels and hippocampal volumes were not different from controls.	N-acetylaspartate	79-82	regulator of microtubule dynamics 1	Homo sapiens	23-27	
20805522-8	2010	CONCLUSION: (1)H MRS metabolite abnormalities characterized by an elevated mI/Cr and decreased NAA/mI are present several years before the onset of symptoms in MAPT mutation carriers.	N-acetylaspartate	95-98	regulator of microtubule dynamics 1	Homo sapiens	160-164